Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) last traded at $3.33 having a low of $3.24 and high of $3.47. This range of trading classifies the stock as one of the day’s most volatile.
It is among the market’s biggest gainers today. Company shares last traded at $3.33 well above $2.49, the stock’s 50 day moving average and significantly above the 200 day moving average of $1.89. The 50 day moving average went up by +33.61% and the 200 day average moved up $1.44.
Traders are more bearish on Arrowhead Pharmaceuticals, Inc. of late if you put credence in the motion in short interest. The firm recorded a rise in short interest of 0.65% between August 15, 2017 and August 31, 2017. Short shares increased 37,973 over that period. The days to cover decreased to 4.0 and the short interest percentage is 0.08% as of August 31.
Recent Analyst Ratings
On September 18 the stock rating was upgraded to “Outperform” from “” by William Blair. In the latest earnings report the EPS was $-0.64 and is estimated to be $-0.42 for the current year with 74,772,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.14 and the next full year EPS is anticipated to be $-0.66.
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, launched on February 13, 2001, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Business’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Business’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Business’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2..